Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor

IPO/OfferingPositive

AI Analysis

Summary

Two biotechs have signed reverse merger agreements to go public on Nasdaq, one advancing a bispecific antibody for immunological/inflammatory diseases and another with a BTK inhibitor sourced from Gossamer Bio.

Outcome Details

Two biotechs signed reverse mergers to list on Nasdaq

Importance:5/10

Sentiment:

0.60

reverse mergerNasdaq listingbispecific antibodyBTK inhibitorrare diseaseimmunology

Related Companies

$INTI $CHHE

Read the original article

Published by Endpoints News on July 29, 2026 2:46 PM

Read Original